Homepage Top Section2

The agreement between Bristol Myers Squibb and Dragonfly Therapeutics includes DF6002, an extended half-life IL12 cytokine, which is being studied as a treatment for advanced solid tumours in

The acceptance of IND will allow Enzychem to assess EC-18 in a phase 2 clinical study in patients with ARDS due to Covid-19. The EC-18 is originally obtained

According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective

Presently, Veklury is being administered to hospitalised patients with severe Covid-19 under an emergency use authorisation (EUA) issued by the FDA. According to Gilead Sciences, the latest drug

The deal between the firms allows Takeda Pharmaceutical to undertake the local production and commercialisation of NVX‑CoV2373 in Japan, which will be backed by funding from the Japanese

Evrysdi is a survival of motor neuron 2 (SMN2) splicing modifier created for the treatment of SMA caused by mutations in chromosome 5q, which lead to SMN protein

The approval will enable ViiV Healthcare to use the complete regimen as a replacement for the current antiretroviral (ARV) regimen in adults who are virologically suppressed on a

Sisunatovir is an orally administered fusion inhibitor designed to inhibit RSV replication by suppressing RSV F-mediated fusion of RSV with the host cell. RSV is a respiratory pathogen

Psoriasis, a life-long systemic inflammatory disease, is said to significantly affect the patients’ quality of life, both physically and emotionally. Cosentyx is claimed to be the first and